$MDXH

MVM Partners, LLC (Bednarski Eric) purchased $1,000K of MDXH (indirect holdings)

MVM Partners, LLC purchased 2,202,643 indirectly-held shares of MDxHealth SA (MDXH) at $0.45 ($1.00M total) on 2026-08-13. Filed jointly with Bednarski Eric (Director).

Original reporting
SEC EDGAR · MVM Partners, LLC, Bednarski Eric
Published Aug 17, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MDXH
Bullish
medium confidence
Mentioned
$MDXH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDXHBullishLow
01

Why it matters

A director-linked open-market purchase increases the probability of bullish sentiment, but the filing lacks any new fundamental information (no guidance, trial, or regulatory update).

02

Market read

Traders may note the insider buy as a sentiment datapoint, but it is not a fundamental catalyst on its own.

03

What to watch

No 10b5-1 plan is stated, but the filing does not explain intent, timing constraints, or whether the director’s economic exposure is meaningfully different from prior holdings.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

This is an SEC Form 4 insider transaction disclosure for MDxHealth SA (MDXH).

Company-level read

Ticker impact

$MDXHBullishMedium confidence
Context

MDxHealth SA disclosed an open-market purchase by director MVM Partners for 2,202,643 shares at $0.4540 on 2026-08-13.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and short-lived.

Evidence & confidence

Form 4 insider buys can be sentiment-positive, but the article provides no new operating, regulatory, or financial development beyond the transaction details.

Market effects

No clear sector read-through from a single insider purchase without additional company-specific catalysts.

None indicated.

None indicated.

Counterpoint

The buy may reflect liquidity planning or diversification rather than a strong forward-looking signal, especially with indirect holdings.

Key entities

  • MDxHealth SA

    Company whose shares were purchased; subject of the Form 4 disclosure.

  • MVM Partners, LLC

    Reporter for the Form 4, associated with director Eric Bednarski and an indirect holdings purchase.

  • Eric Bednarski

    Director co-reporting owner tied to the indirect holdings transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDXHMed

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.

$MDXHMed

mdxhealth Tissue Test Volume Rebounds 13% Sequentially After Sales Force Restructuring

mdxhealth reported Q2 tissue-based test volume rose 13% sequentially to 12,525 tests, aiding Q2 revenue of $27.2 million, up 16% year over year. Revenue for the first half of 2026 rose 14% to $51.1 million. Liquid Exo mdx volume was 13,578 tests, shifting mix and lowering gross margin to 65.7%. Operating loss widened to $5.1 million. On Aug. 11 it raised $20 million via share placement.

$MDXHMedAI 8/10

MDxHealth revenue up 16% in Q2, affirms FY26 sales guidance

MDxHealth (NASDAQ: MDXH) reported Q2 2026 revenue of $27.2 million, up 16% year over year and 14% sequentially, and reaffirmed FY26 sales guidance of $110 million to $115 million. Gross profit rose to $17.9 million, but adjusted EBITDA turned negative at -$2.3 million. The company also received a Nasdaq minimum bid notice and raised $20 million via a registered direct placement.

$MDXHHighAI 9/10

MDxHealth to Shut Down Resolve UTI Business

MDxHealth SA said it will discontinue its Resolve mdx urinary tract infection test and close its Plano, Texas lab, citing reimbursement challenges after Novitas Solutions reversed a Medicare policy, making continued operation “unsustainable,” according to the company. MDxHealth is contesting a $10.4 million recoupment decision. The move lowers 2026 revenue guidance to $110–$115 million from $137–$140 million.